How many insider trades does FilingIQ track for SLS?

FilingIQ tracks 85 Form 4 insider transactions for SLS (SELLAS Life Sciences Group, Inc.), covering filings from Dec 29, 2017 onwards. 1 of those were filed in the last 90 days.

Are SLS insiders net buyers or net sellers?

Across the full Form 4 history for SLS, 4 transactions (5%) were open-market purchases and 7 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SLS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SLS in?

SELLAS Life Sciences Group, Inc. (SLS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $821.59M.

SLS insider trading

NasdaqCM Healthcare

SELLAS Life Sciences Group, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

5% / 8%

Market cap

$821.59M

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Company website: sellaslifesciences.com

SLS insider activity at a glance

FilingIQ has scored 85 insider transactions for SLS since Dec 29, 2017. The most recent filing in our index is dated Jun 16, 2026.

Across the full history, 4 open-market purchases and 7 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SLS insider trades is 56.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SLS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,204

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 159

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

KALV 133

KalVista Pharmaceuticals, Inc.

Frequently asked

How many insider trades does FilingIQ track for SLS?: FilingIQ tracks 85 Form 4 insider transactions for SLS (SELLAS Life Sciences Group, Inc.), covering filings from Dec 29, 2017 onwards. 1 of those were filed in the last 90 days.
Are SLS insiders net buyers or net sellers?: Across the full Form 4 history for SLS, 4 transactions (5%) were open-market purchases and 7 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SLS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SLS in?: SELLAS Life Sciences Group, Inc. (SLS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $821.59M.

Methodology & sources

Every SLS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.